Dual-Mode Hybrid Discharge Plasma-Activated Injectable Hydrosol for Enhanced Immunotherapeutic Cancer Therapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40914824.
- Also identified by DOI 10.1002/adhm.202502779.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Although cold atmospheric plasma is a promising therapeutic technique for tumor immunotherapy via reactive oxygen and nitrogen species (RONS), the challenges associated with the generation and delivery of these RONS hamper clinical adoption. Herein, a dual-mode hybrid discharge plasma-activated sodium alginate hydrosols (PAH<sub>SA</sub>) is proposed to enhance the antitumor immune response. Gaseous highly reactive RONS are generated by dual-mode hybrid plasma produced by mixed O<sub>3</sub> and NO<sub>x</sub> modes, which are converted into aqueous RONS in PAH<sub>SA</sub> via gas-liquid reactions between plasma and hydrosols. In vitro results indicate that compared with O<sub>3</sub>-PAH<sub>SA</sub> and NO<sub>x</sub>-PAH<sub>SA</sub>, Hybrid-PAH<sub>SA</sub> produces greater immunogenic cell death in cancer cells via the release of RONS. It also mediates the polarization of M2-like macrophages to M1-like macrophages to improve antitumor effects. In vivo studies confirm that Hybrid-PAH<sub>SA</sub> inhibits B16F10 melanoma growth and produces stronger T-cell-mediated antitumor immune responses. Thus, Hybrid-PAH<sub>SA</sub> offers a promising strategy for enhanced plasma-induced cancer immunotherapy.
Medical subject headings
- Immunotherapy
- Plasma Gases
- Alginates
- Melanoma, Experimental